Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | IAPP | P10997 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178565 | 0.86 | — | — | |
| SCHEMBL10939811 | 0.86 | GABRR1 (0.30) | — | |
| SCHEMBL1182092 | 0.81 | — | — | |
| SCHEMBL619312 | 0.80 | TDP1 (0.69) | TDP1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3987187 | 0.77 | — | — | |
| SCHEMBL30255411 | 0.76 | TDP1 (0.64) | TDP1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8371300 | 0.76 | TDP1 (0.64) | TDP1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8984748 | 0.76 | TDP1 (0.64) | TDP1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| Hydrogen Sulfide SCHEMBL29291893 | 0.76 | TDP1 (0.64) | TDP1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13379743 | 0.76 | TDP1 (0.64) | TDP1ALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453063-B2 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, LLC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9133260-B2 | GIP analog and hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, LLC (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2330124-B1 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS LLC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8895498-B2 | GIP and exendin hybrid polypeptides | ASTRAZENECA PHARMACEUTICALS, LP (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140249299-A1 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | ASTRAZENECA PHARMACEUTICALS LP (US) | 2014-09-04 | — | — | US | disclosed |
| US-8697647-B2 | Hybrid polypeptides with selectable properties | ASTRAZENECA PHARMACEUTICALS LP | 2014-04-15 | — | — | US | disclosed |
| US-20130281374-A1 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | ASTRAZENECA PHARMACEUTICALS LP (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130196913-A1 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | ASTRAZENECA PHARMACEUTICALS LP (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2057188-B1 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8497240-B2 | DPP-IV resistant GIP hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, LLC (US) | 2013-07-30 | — | — | US | disclosed |
| EP-1922336-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | Amylin Pharmaceuticals, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1718665-A4 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS INC (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008021560-A2 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1853627-A2 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | Amylin Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007022123-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060293232-A1 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1718665-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | Amylin Pharmaceuticals, Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006086769-A2 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060094652-A1 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
| WO-2005077072-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293232-A1 | Hybrid polypeptides with selectable properties | IAPP, IGFBP1, PGF | TDP1 2706/4885ALDH1A1 4324/4885NPC1 1278/4885 |
| US-20130196913-A1 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | GIPR, GLP1R, VIP | TDP1 3446/4885ALDH1A1 4732/4885NPC1 1399/4885 |
| US-20140249299-A1 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | IAPP, IGFBP1, PGF | TDP1 2706/4885ALDH1A1 4324/4885NPC1 1278/4885 |
| US-20130281374-A1 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | GIPR, DPP4, GLP1R | TDP1 2149/4885ALDH1A1 4470/4885NPC1 1379/4885 |
| US-20060094652-A1 | Hybrid polypeptides with selectable properties | IAPP, IGFBP1, PGF | TDP1 2706/4885ALDH1A1 4324/4885NPC1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.